Agranulocytosis News and Research

RSS

Comparing clinical characteristics and outcomes of critically ill COVID-19 patients with a chohort admitted to ICU for influenza pneumonia

A recent study evaluated clinical differences between critically ill COVID-19 and influenza patients.

19 May 2023

New article reviews poor life expectancy associated with treatment-resistant schizophrenia

The vast majority of reviews on psychotropic drugs is focused on the potential benefits that may have. However, the vulnerabilities induced by treatment need also to be considered.

31 Jul 2020

Best proven drug to treat schizophrenia could be safely given to African descent people

A study led by researchers at Cardiff University means that more people of African descent who have treatment-resistant schizophrenia could be safely given the drug best proven to manage their symptoms.

27 Feb 2019

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

FDA grants clearance to new blood cell count test that allows faster availability of results

The U.S. Food and Drug Administration today cleared a complete blood cell count (CBC) test that, based on its categorization, can be run in more health care settings, including physicians' offices, clinics or other types of health care facilities, by a wider range of personnel (e.g. support staff). This broadened test access will allow for faster availability of results.

6 Nov 2017

Researchers find gene variants that predict adverse effects of hyperthyroidism drugs

Researchers and doctors at Uppsala University, along with Swedish and international collaboration partners, have found gene variants that predict the risk of a serious adverse reaction to drugs used for the treatment of hyperthyroidism. The results are published in The Lancet Diabetes & Endocrinology.

4 May 2016

Researchers identify severe side effects of Clozapine drug

Clozapine (CLZ) is a "gold standard" drug for managing treatment-resistant schizophrenia (TRS), who do not respond adequately to first-line antipsychotics.

7 Apr 2016

New study compares effectiveness of clozapine with standard antipsychotics in adults with schizophrenia

In real-world settings, patients with schizophrenia whose symptoms do not respond to standard antipsychotic medications have better outcomes if they are switched to clozapine instead of another standard antipsychotic. They have fewer hospitalizations, stay on the new medication longer, and are less likely to need to use additional antipsychotics.

6 Nov 2015

New research findings on Graves' disease to be highlighted at ATA meeting

A unique mouse model of Graves' disease, an autoimmune disorder that causes hyperthyroidism, and new research findings that may help improve the treatment of Graves' disease will be highlighted in oral and poster presentations at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.

30 Oct 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Dipyrone may reduce brain damage after stroke

An older nonsteroidal anti-inflammatory drug (NSAID) called dipyrone may offer a new approach to reducing injury to brain tissue after a stroke, according to a study in the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

17 Nov 2011

ApoPharma receives FDA approval for Ferriprox to treat transfusional iron overload

The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

15 Oct 2011

ODAC recommends ApoPharma's Ferriprox for FDA approval to treat transfusional iron overload

ApoPharma Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 10 - 2 to recommend that the FDA grant accelerated approval of Ferriprox (deferiprone), an oral iron chelator, for the treatment of patients with transfusional iron overload when current chelation therapy is inadequate.

15 Sep 2011

Cocaine contaminated with livestock de-worming drug causes painful purpura

If the obvious reasons for avoiding recreational drug use aren't off-putting enough, physicians have yet another detrimental consequence to add to the list - crusty, purplish areas of dead skin that are extremely painful and can open the door to nasty infections.

24 Jun 2011

Contaminated cocaine may lead to public health epidemic

Doctors warned of a potential public health epidemic in a recent report on patients in Los Angeles and New York who developed serious skin reactions after smoking or snorting cocaine believed to be contaminated with a veterinary medication drug dealers are using to dilute, or "cut," up to 70% of the cocaine in the U.S.

20 Jun 2011

Contaminant in cocaine impairs immune systems

Toxicologists across the country are sounding the alarm about a contaminant increasingly found in cocaine that is impairing cocaine users' immune systems, subjecting them to various infections and, in some cases, causing death.

26 May 2010

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

Spectral Modeling technology substantiated through creation of antipsychotic bank of drug candidates

LIUS Molecular Design is pleased to announce that it has successfully created two antipsychotic drug candidates with third party confirmation of predicted biological activities via in vitro testing.

19 May 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Treatment of children and adolescents with schizophrenia

There is a wealth of scientific literature available on the treatment of adults diagnosed with schizophrenia.

28 Feb 2008